Progress of relapse after allogeneic hematopoietic stem cell transplantation / 白血病·淋巴瘤

ABSTRACT

Hematologic neoplasm relapse remains one of the major causes of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Relaspe prediction, prophylaxis and treatment after allo-HSCT are the key issues for improving the therapeutic effects and prognosis. This paper chooses some representative reports from 60th American Society of Hematology (ASH) Annual Meeting to discuss the progress of allo-HSCT.